Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Circ Res. Author manuscript; available in PMC 2016 July 3.
Published in final edited form as:
PMCID: PMC4493766

MMP17/MT4-MMP and thoracic aortic aneurysms: OPNing new potential for effective treatment

In recent years, many advances have been made in understanding the pathophysiology of thoracic aortic aneurysms and dissections (TAAD). Mutations in a number of genes leading to aneurysm formation have been identified thus far, and include extracellular matrix (ECM) genes (FBN1, COL3A1, EFEMP2, MFAP5), molecules involved in TGFβ signaling (TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3), and genes involved in regulation of the smooth muscle cell (SMC) contractile apparatus (MYH11, ACTA2, MYLK, PRKG1)13. However, for the majority of TAAD patients, a causative genetic mutation has not yet been identified4. A whole-exome sequencing approach to identifying new genes predisposing to TAAD has provided a means of rapidly identifying additional genetic alterations5.

Studies using mouse models have recapitulated some key molecular pathways disrupted by mutations in currently-identified TAAD genes, including angiotensin II and TGF-β mediated signaling pathways, vascular smooth muscle cell (SMC) phenotype, and pathways regulating SMC contractile function69. Additionally, multiple studies have highlighted the importance of the connections formed between the concentric layers of elastic fibers and SMCs in the aortic wall for transducing mechanical signals and maintaining vascular contractility and homeostasis4.

Despite advances in our understanding of the mechanisms underlying the development of aortic aneurysms, current pharmacologic treatment of TAAD is limited. β-adrenergic receptor blockers are currently recommended for reducing aortic wall stress and potentially slowing the rate of aneurysm growth10. Angiotensin II receptor blocker (ARB) losartan showed great potential in preventing aortic aneurysms in a mouse model of Marfan syndrome: however, a larger scale clinical trial in Marfan patients showed losartan and the β-adrenergic receptor blocker atenolol to be equally effective11. Angiotensin converting enzyme (ACE) inhibitors and ARBs were used in a cohort of patients with abdominal aortic aneurysms (AAAs) and resulted in reduced mortality rates but no reduction in the rate of surgeries to repair AAAs12. Additionally, an ACE inhibitor was reported to reduce both aortic stiffness and aortic root expansion in a small group of Marfan patients, but a larger scale study has not been conducted10, 13. Therefore, an increased understanding of the underlying molecular mechanisms in aneurysm formation and/or factors predisposing individuals to TAAD is needed in order to identify additional therapeutic targets for slowing aneurysm growth and preventing the disease.

One of the hallmark characteristics of pathology for both thoracic and abdominal aneurysms is matrix degradation, and matrix metalloproteinases (MMPs) are well-established culprits in promoting this degradation, regardless of the underlying mutation14, 15. The MMP family of proteins has 23 members including five cell surface bound MT-MMPs, with many substrates identified, including both ECM and matricellular proteins16. MMP2 and MMP9 are the most well-studied elastin degrading MMPs in both thoracic and abdominal aneurysms15. MMP14 and MMP19 were also reported to be increased in TAA17. Their role in matrix degradation has led to the idea that blocking of MMPs should either slow or prevent aortic disease progression. Treatment with doxycycline improved the aneurysm phenotype in a fibrillin-1 hypomorphic mouse model of Marfan syndrome (mgR/mgR)18, and survival time was increased by breeding onto an Mmp2-null background19. Although initially promising in mouse models, the use of doxycycline to treat AAA has had mixed results20. Interestingly, in mice, deletion of Mmp2 improved the aortic phenotype in CaCl2-induced AAA; however, this resulted in increased susceptibility to TAA after angiotensin II infusion21. Taken together, these studies highlight the complex role of MMPs in aneurysm formation.

The diversity of MMP substrates and their effects on the aortic wall adds an additional layer of complexity to the role(s) of MMPs in TAAD. However, for some MMPs, including MMP17/MT4-MMP, relatively few substrates have been confirmed, and substrate identification is an ongoing process22. Osteopontin (OPN) is a matricellular protein highly expressed in the aortic wall and is shown to be targeted for cleavage by MMP -2, -3, -7, -9, and -1223. OPN promotes atherosclerosis through its functions in SMC survival, adhesion, and migration, promotes inflammation of carotid plaques in hypertensive patients24 and mitigates vascular calcification25. When considering the importance of transduction of mechanical signals in the aortic wall, OPN is of particular interest since it contains an arginine-glycine-aspartate (RGD) sequence as well as a cryptic integrin-binding site revealed by proteolytic cleavage by thrombin26. The N-terminal domain of OPN can also act on MMPs by enhancing the activity of pro-MMP927. Furthermore, OPN has been found to be increased in some instances of TAA15. However, much still remains unknown about specific functions of OPN in the aortic wall, and its role in aneurysm formation, including the degree to which it is cleaved in the aortic wall.

In this issue of Circulation Research, Martín-Alonso et al. reported a missense mutation in MMP17 gene (p.Arg373His) as the possible causal mutation for acute ascending aortic aneurysms by using whole exome sequencing28. The R373H mutation was predicted to cause a conformational change in the C-terminal region that hinders the binding of the GPI-tail to the endoplasmic reticulum and form an energy unstable heterodimer with wild-type MMP17. Indeed, the authors showed compromised expression of R373H protein in transfected cells, suggesting a functional homozygous loss, which is surprising considering the well-known functions of MMPs as matrix degrading enzymes and the increased expression reported in aortic aneurysms in mice and humans29, 30.

The authors then turned into a mouse model (Mmp17−/−) to investigate the impact of loss of MMP17 in the aortic development and aneurysm formation. Although these mice showed a marginal increase in aortic lumen diameter, no spontaneous aneurysm or dissection was observed. However, when challenged with chronic infusion of angiotensin II or carotid artery ligation, the mutants exhibited higher incidence of TAA (but not AAA) and developed more prominent neointimas, respectively, suggesting an altered response to pathological stimuli and dysfunctional SMCs. Ultrastructural analyses revealed various morphological abnormalities in the Mmp17−/− aorta, including radially oriented SMCs with round cell shape, disconnection of SMCs from elastin lamelli, an increase in collagen fibers, altered distribution of SMC marker proteins, and a transient increase in proliferating SMCs, affecting the maturation of SMCs (Figure).

Loss of MMP17 affects maturation of vascular smooth muscle cell (VSMC) and integrity of the aortic wall

During mouse embryogenesis, SMC progenitors from various embryonic origins migrate and surround the endothelial tube in a location-specific manner beginning at around E10.5 and gradually add layers of SMCs to form the aortic wall (reviewed in31). The majority of vascular ECM proteins, including fibrillar collagens (I, III, and VI), elastin, and fibrillin-1, are upregulated at around E14.5 following the recruitment of SMC progenitors and continue to be expressed until the early postnatal period32. These ECM proteins provide structural support with tensile strength and elasticity and form connections with SMCs33. Interestingly, Mmp17 expression was detected in peri-aortic progenitors at E10.5–11.5 and peaked at E14.0, suggesting a potential role for MMP17 in the early construction of the aortic wall and SMC maturation. This led to two important questions. First, what is the molecular mechanism of MMP17 function in these processes? Second, is the proteolytic activity required for the MMP17 function, and if so, what are the biologically relevant substrate(s) for MMP17?

The authors addressed these questions first by showing that lentivirus-mediated rescue of the aortic phenotype in MMP-17−/− mice was dependent on the catalytic activity of MMP-17. What is surprising, however, is that although MMP-17 exerts its function during embryogenesis, immediate postnatal restoration of MMP17 activity was sufficient to achieve full rescue of the Mmp17−/− aorta. Second, the authors employed SILAC (stable isotope labeling of amino acids in culture) to compare protein expression between wild-type and Mmp17−/− cells and identified OPN as a putative substrate among others for MMP17-mediated cleavage. The authors determined that the cleavage site was between Asp210 –Leu 211 in human OPN, which was consistent with a previously determined MMP cleavage site34, and demonstrated the presence of liberated N-terminal OPN fragments (N-OPN) in the developing aorta, which was reduced in the Mmp17−/− aorta and led to decreased amounts of phospho-JNK. Re-introduction of N-OPN, but not full length OPN, restored phospho-JNK levels and reduced phospho-H3-positive proliferating cells in the aortic wall and improved SMC morphology in vitro, establishing a cleavage-specific function of OPN in vivo.

Martín-Alonso et al. provided compelling evidence for the biological function of N-OPN generated by MMP17 in the aortic development. However, the results from this study also raise several important questions for follow-up. First, OPN was shown to be cleaved by multiple proteases, including MMP3, MMP7, thrombin, plasmin and cathepsin D at multiple sites containing the RGD sequence26, 34, 35. How is the specificity of OPN cleavage by MMP17 determined during embryogenesis? Is MMP17 the only relevant protease expressed at the right time and right location? Second, what is the signaling pathway for N-OPN and its relationship with full-length OPN? The RGD site in OPN has been shown to bind subsets of integrin heterodimers, including αvβ3, αvβ1, α5β1, and α8β1 (reviewed in36). The differential biochemical activities for N-OPN and full-length OPN have begun to be addressed in various disease settings24, 37. Experiments using purified proteins in cell culture system should allow for comparison of the differential effects on migration and proliferation of vascular SMCs. Thirdly, the intracellular signaling pathway mediated by N-OPN was shown to involve p-JNK; however, p-JNK positive cells constitute a subset of cells in the developing aorta. The nature of these p-JNK positive cells, including whether they represent specific progenitor cell population or how they contribute to the maturation of entire aortic wall, warrants further investigation. Fourthly, the authors clearly showed that MMP17 was required for the development of contractile filaments, correct positioning and orientation of SMCs within the elastic lamella, and formation of connections to elastic fibers. This structural continuity between SMC and elastic lamina is essential to prevent development of thoracic aortic aneurysms. In addition, ECM exhibits profound effects on SMC phenotypes38, 39 and induces differential responses to stiffness-induced mechanotransduction40. The current study further demonstrated that remodeling of ECM and liberation of cleaved fragment by MMP17 during embryogenesis plays a critical role in establishing and maintenance of the vessel integrity, although the long-term rescue effects of N-OPN and whether Mmp17−/− aortas with N-OPN overexpression prevents from angiotensin II-induced TAA need to be addressed in future studies. Finally, the identification of a specific MMP17-cleaved OPN fragment raises the question of whether other matricellular or ECM protein fragments cleaved by MMPs also have important roles in the aortic wall. The identification of MMP17 substrates other than OPN may facilitate our understanding of aortic remodeling in pathological conditions accompanied by increased inflammatory responses. Further consideration of the balance between degradation of ECM and generation of ECM fragments is required to develop effective therapeutic strategies using MMP inhibitors for aortic aneurysms.


We thank José Cabrera for assistance with graphics.

Source of Funding

Research projects in Yanagisawa laboratory are supported in part by grants from the NIH (R01HL106305 and R01HD064824) and American Heart Association (12EIA8190000). Christina L. Papke is supported by fellowships from the NIH (5T32HL007360-34 and F32HL122076-01).


thoracic aortic aneurysms and dissections
extracellular matrix
smooth muscle cell
transforming growth factor beta
angiotensin II receptor blocker
angiotensin converting enzyme
abdominal aortic aneurysm
thoracic aortic aneurysm
matrix metalloproteinase
c-Jun N-terminal kinase


Disclosures: None


1. Proost D, Vandeweyer G, Meester JA, Salemink S, Kempers M, Ingram C, Peeters N, Saenen J, Vrints C, Lacro RV, Roden D, Wuyts W, Dietz HC, Mortier G, Loeys BL, Van Laer L. Performant mutation identification using targeted next generation sequencing of fourteen thoracic aortic aneurysm genes. Hum Mutat. 2015 [PubMed]
2. Barbier M, Gross MS, Aubart M, Hanna N, Kessler K, Guo DC, Tosolini L, Ho-Tin-Noe B, Regalado E, Varret M, Abifadel M, Milleron O, Odent S, Dupuis-Girod S, Faivre L, Edouard T, Dulac Y, Busa T, Gouya L, Milewicz DM, Jondeau G, Boileau C. Mfap5 loss-of-function mutations underscore the involvement of matrix alteration in the pathogenesis of familial thoracic aortic aneurysms and dissections. Am J Hum Genet. 2014;95:736–743. [PubMed]
3. Bertoli-Avella AM, Gillis E, Morisaki H, Verhagen JM, de Graaf BM, van de Beek G, Gallo E, Kruithof BP, Venselaar H, Myers LA, Laga S, Doyle AJ, Oswald G, van Cappellen GW, Yamanaka I, van der Helm RM, Beverloo B, de Klein A, Pardo L, Lammens M, Evers C, Devriendt K, Dumoulein M, Timmermans J, Bruggenwirth HT, Verheijen F, Rodrigus I, Baynam G, Kempers M, Saenen J, Van Craenenbroeck EM, Minatoya K, Matsukawa R, Tsukube T, Kubo N, Hofstra R, Goumans MJ, Bekkers JA, Roos-Hesselink JW, van de Laar IM, Dietz HC, Van Laer L, Morisaki T, Wessels MW, Loeys BL. Mutations in a tgf-beta ligand, tgfb3, cause syndromic aortic aneurysms and dissections. J Am Coll Cardiol. 2015;65:1324–1336. [PMC free article] [PubMed]
4. Humphrey JD, Schwartz MA, Tellides G, Milewicz DM. Role of mechanotransduction in vascular biology: Focus on thoracic aortic aneurysms and dissections. Circ Res. 2015;116:1448–1461. [PMC free article] [PubMed]
5. Milewicz DM, Regalado ES, Shendure J, Nickerson DA, Guo DC. Successes and challenges of using whole exome sequencing to identify novel genes underlying an inherited predisposition for thoracic aortic aneurysms and acute aortic dissections. Trends Cardiovasc Med. 2014;24:53–60. [PMC free article] [PubMed]
6. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC. Losartan, an at1 antagonist, prevents aortic aneurysm in a mouse model of marfan syndrome. Science. 2006;312:117–121. [PMC free article] [PubMed]
7. Moltzer E, te Riet L, Swagemakers SM, van Heijningen PM, Vermeij M, van Veghel R, Bouhuizen AM, van Esch JH, Lankhorst S, Ramnath NW, de Waard MC, Duncker DJ, van der Spek PJ, Rouwet EV, Danser AH, Essers J. Impaired vascular contractility and aortic wall degeneration in fibulin-4 deficient mice: Effect of angiotensin ii type 1 (at1) receptor blockade. PLoS One. 2011;6:e23411. [PMC free article] [PubMed]
8. Kuang SQ, Kwartler CS, Byanova KL, Pham J, Gong L, Prakash SK, Huang J, Kamm KE, Stull JT, Sweeney HL, Milewicz DM. Rare, nonsynonymous variant in the smooth muscle-specific isoform of myosin heavy chain, myh11, r247c, alters force generation in the aorta and phenotype of smooth muscle cells. Circ Res. 2012;110:1411–1422. [PMC free article] [PubMed]
9. Huang J, Yamashiro Y, Papke CL, Ikeda Y, Lin Y, Patel M, Inagami T, Le VP, Wagenseil JE, Yanagisawa H. Angiotensin-converting enzyme-induced activation of local angiotensin signaling is required for ascending aortic aneurysms in fibulin-4-deficient mice. Sci Transl Med. 2013;5:183ra158, 181–111. [PMC free article] [PubMed]
10. Braverman AC. Medical management of thoracic aortic aneurysm disease. J Thorac Cardiovasc Surg. 2013;145:S2–S6. [PubMed]
11. Lacro RV, Dietz HC, Sleeper LA, Yetman AT, Bradley TJ, Colan SD, Pearson GD, Selamet Tierney ES, Levine JC, Atz AM, Benson DW, Braverman AC, Chen S, De Backer J, Gelb BD, Grossfeld PD, Klein GL, Lai WW, Liou A, Loeys BL, Markham LW, Olson AK, Paridon SM, Pemberton VL, Pierpont ME, Pyeritz RE, Radojewski E, Roman MJ, Sharkey AM, Stylianou MP, Wechsler SB, Young LT, Mahony L. Pediatric Heart Network I. Atenolol versus losartan in children and young adults with marfan's syndrome. N Engl J Med. 2014;371:2061–2071. [PMC free article] [PubMed]
12. Kristensen KE, Torp-Pedersen C, Gislason GH, Egfjord M, Rasmussen HB, Hansen PR. Angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers in patients with abdominal aortic aneurysms: Nation-wide cohort study. Arterioscler Thromb Vasc Biol. 2015;35:733–740. [PubMed]
13. Ahimastos AA, Aggarwal A, D'Orsa KM, Formosa MF, White AJ, Savarirayan R, Dart AM, Kingwell BA. Effect of perindopril on large artery stiffness and aortic root diameter in patients with marfan syndrome: A randomized controlled trial. JAMA. 2007;298:1539–1547. [PubMed]
14. Milewicz DM, Guo DC, Tran-Fadulu V, Lafont AL, Papke CL, Inamoto S, Kwartler CS, Pannu H. Genetic basis of thoracic aortic aneurysms and dissections: Focus on smooth muscle cell contractile dysfunction. Annu Rev Genomics Hum Genet. 2008;9:283–302. [PubMed]
15. Huusko T, Salonurmi T, Taskinen P, Liinamaa J, Juvonen T, Paakko P, Savolainen M, Kakko S. Elevated messenger rna expression and plasma protein levels of osteopontin and matrix metalloproteinase types 2 and 9 in patients with ascending aortic aneurysms. J Thorac Cardiovasc Surg. 2013;145:1117–1123. [PubMed]
16. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014;15:786–801. [PMC free article] [PubMed]
17. Jackson V, Olsson T, Kurtovic S, Folkersen L, Paloschi V, Wagsater D, Franco-Cereceda A, Eriksson P. Matrix metalloproteinase 14 and 19 expression is associated with thoracic aortic aneurysms. J Thorac Cardiovasc Surg. 2012;144:459–466. [PubMed]
18. Xiong W, Knispel RA, Dietz HC, Ramirez F, Baxter BT. Doxycycline delays aneurysm rupture in a mouse model of marfan syndrome. J Vasc Surg. 2008;47:166–172. discussion 172. [PMC free article] [PubMed]
19. Xiong W, Meisinger T, Knispel R, Worth JM, Baxter BT. Mmp-2 regulates erk1/2 phosphorylation and aortic dilatation in marfan syndrome. Circ Res. 2012;110:e92–e101. [PMC free article] [PubMed]
20. Dodd BR, Spence RA. Doxycycline inhibition of abdominal aortic aneurysm growth: A systematic review of the literature. Curr Vasc Pharmacol. 2011;9:471–478. [PubMed]
21. Shen M, Lee J, Basu R, Sakamuri SS, Wang X, Fan D, Kassiri Z. Divergent roles of matrix metalloproteinase 2 in pathogenesis of thoracic aortic aneurysm. Arterioscler Thromb Vasc Biol. 2015;35:888–898. [PubMed]
22. Stegemann C, Didangelos A, Barallobre-Barreiro J, Langley SR, Mandal K, Jahangiri M, Mayr M. Proteomic identification of matrix metalloproteinase substrates in the human vasculature. Circ Cardiovasc Genet. 2013;6:106–117. [PubMed]
23. Wolak T. Osteopontin - a multi-modal marker and mediator in atherosclerotic vascular disease. Atherosclerosis. 2014;236:327–337. [PubMed]
24. Wolak T, Sion-Vardi N, Novack V, Greenberg G, Szendro G, Tarnovscki T, Nov O, Shelef I, Paran E, Rudich A. N-terminal rather than full-length osteopontin or its c-terminal fragment is associated with carotid-plaque inflammation in hypertensive patients. Am J Hypertens. 2013;26:326–333. [PubMed]
25. Jono S, Peinado C, Giachelli CM. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem. 2000;275:20197–20203. [PubMed]
26. Senger DR, Perruzzi CA, Papadopoulos-Sergiou A, Van de Water L. Adhesive properties of osteopontin: Regulation by a naturally occurring thrombin-cleavage in close proximity to the grgds cell-binding domain. Mol Biol Cell. 1994;5:565–574. [PMC free article] [PubMed]
27. Lai CF, Seshadri V, Huang K, Shao JS, Cai J, Vattikuti R, Schumacher A, Loewy AP, Denhardt DT, Rittling SR, Towler DA. An osteopontin-nadph oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cells. Circ Res. 2006;98:1479–1489. [PubMed]
28. Martin-Alonso M, Garcia-Redondo AB, Guo D, Camafeita E, Martinez F, Alfranca A, Mendez-Barbero N, Pollan A, Sanchez-Camacho C, Denhardt DT, Seiki M, Vazquez J, Salaices M, Redondo JM, Milewicz DM, Arroyo AG. Deficiency of mmp17/mt4-mmp proteolytic activity predisposes to aortic aneurysm in mice. Circ Res. 2015 [PubMed]
29. Xiong W, Knispel R, MacTaggart J, Greiner TC, Weiss SJ, Baxter BT. Membrane-type 1 matrix metalloproteinase regulates macrophage-dependent elastolytic activity and aneurysm formation in vivo. J Biol Chem. 2009;284:1765–1771. [PMC free article] [PubMed]
30. Wilson WR, Anderton M, Choke EC, Dawson J, Loftus IM, Thompson MM. Elevated plasma mmp1 and mmp9 are associated with abdominal aortic aneurysm rupture. Eur J Vasc Endovasc Surg. 2008;35:580–584. [PubMed]
31. Majesky MW. Developmental basis of vascular smooth muscle diversity. Arterioscler Thromb Vasc Biol. 2007;27:1248–1258. [PubMed]
32. Kelleher CM, McLean SE, Mecham RP. Vascular extracellular matrix and aortic development. Curr Top Dev Biol. 2004;62:153–188. [PubMed]
33. Davis EC. Smooth muscle cell to elastic lamina connections in developing mouse aorta. Role in aortic medial organization. Lab Invest. 1993;68:89–99. [PubMed]
34. Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC, Liaw L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin) J Biol Chem. 2001;276:28261–28267. [PubMed]
35. Christensen B, Schack L, Klaning E, Sorensen ES. Osteopontin is cleaved at multiple sites close to its integrin-binding motifs in milk and is a novel substrate for plasmin and cathepsin d. J Biol Chem. 2010;285:7929–7937. [PMC free article] [PubMed]
36. Scatena M, Liaw L, Giachelli CM. Osteopontin: A multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007;27:2302–2309. [PubMed]
37. Albertsson AM, Zhang X, Leavenworth J, Bi D, Nair S, Qiao L, Hagberg H, Mallard C, Cantor H, Wang X. The effect of osteopontin and osteopontin-derived peptides on preterm brain injury. J Neuroinflammation. 2014;11:197. [PMC free article] [PubMed]
38. Karnik SK, Brooke BS, Bayes-Genis A, Sorensen L, Wythe JD, Schwartz RS, Keating MT, Li DY. A critical role for elastin signaling in vascular morphogenesis and disease. Development. 2003;130:411–423. [PubMed]
39. Huang J, Davis EC, Chapman SL, Budatha M, Marmorstein LY, Word RA, Yanagisawa H. Fibulin-4 deficiency results in ascending aortic aneurysms: A potential link between abnormal smooth muscle cell phenotype and aneurysm progression. Circ Res. 2010;106:583–592. [PMC free article] [PubMed]
40. Sazonova OV, Isenberg BC, Herrmann J, Lee KL, Purwada A, Valentine AD, Buczek-Thomas JA, Wong JY, Nugent MA. Extracellular matrix presentation modulates vascular smooth muscle cell mechanotransduction. Matrix Biol. 2015;41:36–43. [PubMed]